Latest & greatest articles for metformin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on metformin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on metformin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for metformin

101. Metformin decreases progerin expression and alleviates pathological defects of Hutchinson–Gilford progeria syndrome cells Full Text available with Trip Pro

Metformin decreases progerin expression and alleviates pathological defects of Hutchinson–Gilford progeria syndrome cells Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic disorder that causes systemic accelerated aging in children. This syndrome is due to a mutation in the LMNA gene that leads to the production of a truncated and toxic form of lamin A called progerin. Because the balance between the A-type lamins is controlled by the RNA-binding protein SRSF1, we have (...) hypothesized that its inhibition may have therapeutic effects for HGPS. For this purpose, we evaluated the antidiabetic drug metformin and demonstrated that 48 h treatment with 5 mmol/l metformin decreases SRSF1 and progerin expression in mesenchymal stem cells derived from HGPS induced pluripotent stem cells (HGPS MSCs). The effect of metformin on progerin was then confirmed in several in vitro models of HGPS, i.e., human primary HGPS fibroblasts, LmnaG609G/G609G mouse fibroblasts and healthy MSCs

2016 NPJ aging and mechanisms of disease

102. [Empagliflozin/metformin]

[Empagliflozin/metformin] Empagliflozin/metformin (diabetes mellitus Typ 2): addendum zum auftrag A16-13; auftrag A16-47 [Empagliflozin/metformin - addendum to commission A16-13] Empagliflozin/metformin (diabetes mellitus Typ 2): addendum zum auftrag A16-13; auftrag A16-47 [Empagliflozin/metformin - addendum to commission A16-13] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health technology assessment from (...) a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Empagliflozin/metformin (diabetes mellitus Typ 2): addendum zum auftrag A16-13; auftrag A16-47. [Empagliflozin/metformin - addendum to commission A16-13] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 418. 2016 Final publication URL Indexing Status Subject indexing

2016 Health Technology Assessment (HTA) Database.

103. Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study) Full Text available with Trip Pro

Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study) Gemigliptin is a new dipeptidyl peptidase-IV inhibitor. We investigated the efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes (T2D).A total of 433 T2D patients (...) with a glycosylated haemoglobin (HbA1c) level of 7.5% to 11.0% and a fasting plasma glucose (FPG) concentration <270 mg/dL were randomly assigned to 3 groups: (1) gemigliptin 50 mg qd + metformin 1000 to 2000 mg qd (titrated individually), (2) gemigliptin 50 mg qd, or (3) metformin 1000 to 2000 mg qd. The primary end-point was the change in HbA1c level after 24 weeks. Secondary end-points were the changes in FPG, insulin, proinsulin and C-peptide levels. The percentages of responders who achieved an HbA1c level

2016 EvidenceUpdates

104. Metformin Use in Patients with Historical Contraindications or Precautions

Metformin Use in Patients with Historical Contraindications or Precautions Management Briefs eBrief-no116 -- Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs eBrief-no116 -- Health Services Research & Development Management eBrief no. 116 » Issue 116 October 2016 The report is a product of the VA/HSR&D Evidence Synthesis Program. Metformin Use in Patients with Historical (...) Contraindications or Precautions Metformin is an oral hypoglycemic medication used primarily for treating type 2 diabetes mellitus. Evidence suggests that in addition to improving glycemic control, metformin may be associated with improved all-cause and cardiovascular mortality and decreased risk of some cancers. However, clinicians have traditionally been advised by the U.S. Food and Drug Administration (FDA) to exercise caution in prescribing metformin to individuals with chronic kidney disease (CKD

2016 Veterans Affairs - R&D

105. Use of metformin to treat diabetes now expanded to patients with moderately reduced kidney function

Use of metformin to treat diabetes now expanded to patients with moderately reduced kidney function Use of metformin to treat diabetes now expanded to patients with moderately reduced kidney function | European Medicines Agency Search Search Menu Use of metformin to treat diabetes now expanded to patients with moderately reduced kidney function Press release 14/10/2016 Recommendations for patients with kidney impairment updated in The European Medicines Agency (EMA) has concluded that metformin (...) -containing medicines can now be used in patients with moderately reduced kidney function (GFR [glomerular filtration rate]=30–59 ml/min) for the treatment of type 2 diabetes. The for these medicines will be updated to revise the current contraindication and give information about doses, monitoring and precautions in patients with reduced kidney function. The recommendations are the result of a review by EMA of metformin-containing medicines following concerns that current scientific evidence does

2016 European Medicines Agency - EPARs

106. Does metformin reduce excess birthweight in offspring of obese pregnant women? A randomised controlled trial of efficacy, exploration of mechanisms and evaluation of other pregnancy complications Full Text available with Trip Pro

Does metformin reduce excess birthweight in offspring of obese pregnant women? A randomised controlled trial of efficacy, exploration of mechanisms and evaluation of other pregnancy complications Does metformin reduce excess birthweight in offspring of obese pregnant women? A randomised controlled trial of efficacy, exploration of mechanisms and evaluation of other pregnancy complications Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found (...) Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Metformin taken by obese pregnant women did not reduce their baby's birthweight. {{author}} {{($index , , , , , , , , , , , , , , , , , , , , , & . Carolyn A Chiswick 1 , Rebecca M Reynolds 2 , Fiona C Denison 1 , Amanda J

2016 NIHR HTA programme

107. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION) (Abstract)

Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION) To compare the efficacy and safety of combination of vildagliptin and metformin therapy with metformin uptitration in Chinese patients with type 2 diabetes (T2DM) inadequately controlled with low-dose metformin.In this 24-week prospective (...) , randomized, multicentre, open-label study, patients with T2DM inadequately controlled with metformin ≤1000 mg daily were divided 1 : 1 : 1 : 1 into four prespecified subgroups based on age and body mass index (BMI). Patients in each subgroup were randomized 5 : 1 to receive either vildagliptin (50 mg twice daily) plus metformin [500 mg twice daily; vildagliptin and low-dose metformin (VLDM) group] or metformin uptitration [1000 mg twice daily; high-dose metformin (HDM) group]. The primary endpoint

2016 EvidenceUpdates Controlled trial quality: uncertain

108. [Empagliflozin/metformin: benefit assessment according to õ35a Social Code Book V]

[Empagliflozin/metformin: benefit assessment according to õ35a Social Code Book V] Empagliflozin/Metformin: nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A16-1 [Empagliflozin/metformin: benefit assessment according to §35a Social Code Book V] Empagliflozin/Metformin: nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A16-1 [Empagliflozin/metformin: benefit assessment according to §35a Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (...) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Empagliflozin/Metformin: nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A16-1. [Empagliflozin/metformin: benefit assessment according to §35a Social Code Book V] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit

2016 Health Technology Assessment (HTA) Database.

109. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register (Abstract)

Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register To investigate the relative safety of various glucose-lowering agents as add-on medication to metformin in type 2 diabetes in an observational study linking five national health registers.Patients with type 2 diabetes who had been on metformin monotherapy and started another agent in addition to metformin were eligible for inclusion (...) treatment was associated with significantly lower risks of CVD, fatal CVD, CHD, fatal CHD and CHF.This nationwide observational study showed that second-line treatment with TZD and DPP-4 inhibitor as add-on medication to metformin were associated with significantly lower risks of mortality and cardiovascular events compared with SU, whereas basal insulin was associated with a higher risk of mortality.© 2016 John Wiley & Sons Ltd.

2016 EvidenceUpdates

110. Glucose Control in Severely Burned Patients Using Metformin: An Interim Safety and Efficacy Analysis of a Phase II Randomized Controlled Trial (Abstract)

Glucose Control in Severely Burned Patients Using Metformin: An Interim Safety and Efficacy Analysis of a Phase II Randomized Controlled Trial To determine whether metformin can achieve glucose control no worse than insulin (noninferiority) without the danger of hypoglycemia (superiority). In addition, to assess whether metformin has any additional effects on lipolysis and inflammation that will enhance burn recovery (superiority).Hyperglycemia and insulin resistance after burn injury (...) are associated with increased morbidity and mortality. Insulin administration improves postburn infections, severity of sepsis, and morbidity, but also causes a 4-5-fold increase in hypoglycemia, which is associated with a 9-fold increase in mortality.Severely burned adult patients with burns over 20% total body surface area (TBSA) burn were prospectively randomized in this Phase II clinical trial to either metformin or insulin (standard of care) treatment. Primary outcomes were glucose levels and incidence

2016 EvidenceUpdates Controlled trial quality: uncertain

111. Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study. Full Text available with Trip Pro

Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study.  To determine the association between use of sulphonylureas and risk of hypoglycaemia in relation to renal function and sulphonylurea metabolic group compared with use of metformin. Population based cohort study using routinely collected data from general practices in England. Clinical Practice Research Datalink (CPRD) database (...) for age, sex, lifestyle, comorbidity, and drug use. The risk of hypoglycaemia in current users of sulphonylureas only was significantly increased compared with current users of metformin only (adjusted hazard ratio 2.50, 95% confidence interval 2.23 to 2.82). The higher risk in current users of sulphonylureas only was further increased in patients with an estimated glomerular filtration rate of less than 30 mL/min/1.73 m(2) (4.96, 3.76 to 6.55). The risk of hypoglycaemia was also significantly higher

2016 BMJ

112. Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial Full Text available with Trip Pro

Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial To compare the efficacy and safety of liraglutide versus lixisenatide as add-on to metformin in patients with type 2 diabetes not achieving adequate glycemic control on metformin alone.In this 26-week, randomized, parallel-group, open-label trial, 404 patients were randomized 1:1 to liraglutide 1.8 mg or lixisenatide 20 µg as add-on to metformin. Liraglutide (...) for lixisenatide; P = 0.23). The most common adverse events in both groups were gastrointestinal disorders. Greater increases in pulse, lipase, and amylase were observed with liraglutide. Hypoglycemic episodes were rare and similar between the two treatments.At the dose levels studied, liraglutide was more effective than lixisenatide as add-on to metformin in improving glycemic control. Body weight reductions were similar. Both treatments were well tolerated, with low risk of hypoglycemia and similar

2016 EvidenceUpdates Controlled trial quality: uncertain

113. XIGDUO (dapagliflozin/metformin), antidiabetic - type-2 diabetes

XIGDUO (dapagliflozin/metformin), antidiabetic - type-2 diabetes XIGDUO SUMMARY CT14263

2016 Haute Autorite de sante

114. Durable response of glioblastoma to adjuvant therapy consisting of temozolomide and a weekly dose of AMD3100 (plerixafor), a CXCR4 inhibitor, together with lapatinib, metformin and niacinamide Full Text available with Trip Pro

Durable response of glioblastoma to adjuvant therapy consisting of temozolomide and a weekly dose of AMD3100 (plerixafor), a CXCR4 inhibitor, together with lapatinib, metformin and niacinamide Glioblastoma multiforme (GBM) is a CNS (central nervous system) malignancy with a low cure rate. Median time to progression after standard treatment is 7 months and median overall survival is 15 months [1]. Post-treatment vasculogenesis promoted by recruitment of bone marrow derived cells (BMDCs, CD11b

2016 Oncoscience

115. Efficacy and Safety of Titrated Canagliflozin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sitagliptin Full Text available with Trip Pro

Efficacy and Safety of Titrated Canagliflozin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sitagliptin To evaluate the efficacy and safety of titrated canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin and sitagliptin.In this randomized, double-blind study, patients with T2DM (N = 218) on metformin ≥1500 mg/day and sitagliptin 100 mg received canagliflozin 100 mg (...) with placebo (p < 0.001). The overall AE incidence was 39.8 and 44.4% for canagliflozin and placebo, respectively. Canagliflozin was associated with an increased incidence of genital mycotic infections.Titrated canagliflozin significantly improved HbA1c, FPG, body weight and SBP, and was generally well tolerated over 26 weeks in patients with T2DM as add-on to metformin and sitagliptin.© 2016 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

2016 EvidenceUpdates Controlled trial quality: uncertain

116. Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomised, active comparator clinical trial Full Text available with Trip Pro

Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomised, active comparator clinical trial To compare the efficacy and safety of liraglutide versus sitagliptin as add-on to metformin after 26 weeks of treatment in Chinese patients with type 2 diabetes mellitus (T2DM).This 26-week open-label, active comparator trial (NCT02008682) randomized patients (aged 18-80 years) with T2DM (...) inadequately controlled with metformin [glycated haemoglobin (HbA1c) 7.0-10.0% (53-86 mmol/mol)] 1 : 1 to once-daily subcutaneously administered liraglutide 1.8 mg (n = 184) or once-daily oral sitagliptin 100 mg (n = 184), both as add-on to metformin. The primary endpoint was change in HbA1c from baseline to week 26.Liraglutide was superior to sitagliptin in reducing HbA1c from baseline [8.1% (65 mmol/mol)] to 26 weeks, as evidenced by estimated mean HbA1c change of -1.65% (-18.07 mmol/mol) versus -0.98

2016 EvidenceUpdates Controlled trial quality: uncertain

117. Empagliflozin and metformin (Synjardy)

Empagliflozin and metformin (Synjardy) Empagliflozin and metformin | CADTH.ca Find the information you need Empagliflozin and metformin Empagliflozin and metformin Last Updated: April 4, 2016 Result type: Reports Project Number: SR0489-000 Product Line: Generic Name: Empagliflozin and metformin Brand Name: Synjardy Manufacturer: Boehringer Ingelheim (Canada) Ltd. Indications: Diabetes mellitus (Type 2) Submission Type: New Project Status: Complete Date Recommendation Issued: October 25, 2016

2016 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

118. The effect of ranolazine on glycemic control in patients with type 2 diabetes treated with either glimepiride or metformin (Abstract)

The effect of ranolazine on glycemic control in patients with type 2 diabetes treated with either glimepiride or metformin To report the results of two phase III trials assessing the efficacy of ranolazine for glycaemic control in patients with type 2 diabetes on metformin or glimepiride background therapy.In two double-blind trials we randomized 431 and 442 patients with type 2 diabetes to ranolazine 1000 mg twice daily versus placebo added to either glimepiride (glimepiride add-on study (...) ) or metformin background therapy (metformin add-on study). Patients receiving ranolazine added to metformin had their metformin dose halved (with the addition of a metformin-matched placebo) relative to the placebo group to correct for a metformin-ranolazine pharmacokinetic interaction. The primary endpoint of the trials was the change from baseline in glycated haemoglobin (HbA1c) at week 24.When added to glimepiride, ranolazine caused a 0.51% least squares mean [95% confidence interval (CI) 0.71, 0.32

2016 EvidenceUpdates Controlled trial quality: predicted high

119. Canagliflozin and metformin hydrochloride (TBC)

Canagliflozin and metformin hydrochloride (TBC) Canagliflozin and metformin hydrochloride | CADTH.ca Find the information you need Canagliflozin and metformin hydrochloride Canagliflozin and metformin hydrochloride Last Updated: October 10, 2018 Result type: Reports Project Number: SR0480-000 Product Line: Generic Name: Canagliflozin and metformin hydrochloride Brand Name: Invokamet Manufacturer: Janssen Inc. Indications: Diabetes mellitus, type 2 Submission Type: New Project Status: Complete

2016 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

120. Could Metformin be the First Anti-Aging Drug?

Could Metformin be the First Anti-Aging Drug? Could Metformin be the First Anti-Aging Drug? – Clinical Correlations Search Could Metformin be the First Anti-Aging Drug? February 11, 2016 6 min read By Amy Shen Tang, MD P eer Reviewed “I would pay you if you took it away from me. I’d try to buy it back,” said Irving Kahn, the late Wall Street [1]. Mr. Kahn, who founded Kahn Brothers Group, Inc. with his sons more than 40 years ago, took an active role as chair of his company until his passing (...) colleagues at the Institute for Aging Research are looking to make a cheap, generic, widely used drug—metformin—the first to be Food and Drug Association (FDA)-approved for the indication of aging. Metformin is an oral biguanide antidiabetic medication that has been used for over 50 years. It is commonly prescribed as a first-line treatment for type 2 diabetes mellitus and often in combination with other antidiabetic medications including insulin. Metformin reduces blood glucose levels by preventing

2016 Clinical Correlations